Skip Ribbon Commands
Skip to main content

UCHealth Home

:

Clinical Trials: CDX110-06: A Phase II Study of Rindopepimut/GM-CSF in Patients with Relapsed EGFRvIII-Positive Glioblastoma

 


CDX110-06: A Phase II Study of Rindopepimut/GM-CSF in Patients with Relapsed EGFRvIII-Positive Glioblastoma


Trial Focus

Brain and Nervous System Tumors

Objective

         This is a clinical trial of investigational drug of Rindopepimut/GM-CSF which will be administered by injection.

IRB Protocol #

13-1629

Trial Status

Archived

Principle Investigator

DENISE M. DAMEK

Sponsor

Celldex Therapeutics

Contact

MONICA ROBISCHON at (720) 848-0661 or MONICA.ROBISCHON@UCDENVER.EDU

Location

University of Colorado Hospital University of Colorado Hospital

Eligibility and Other Participant Information


What To Expect : A screening period will determine eligibility. You may be taking part in this study for up to 2 years. During the treatment phase you will have visits on day 1, day 15, day 29 and every 28 days thereafter for as long as your study doctor determines that you are still benefitting from the study drug. A follow-up period will include a clinic visit within 28 days of study drug discontinuation. After your disease has progressed, someone at the study site will contact you every 2 months to see what treatments for cancer you are currently receiving and how you are doing // Eligibility includes but are not limited to 18 years or older with Relapsed EGFRvIII-Positive GlioblastomaEligibility includes but are not limited to 18 years or older with Relapsed EGFRvIII-Positive Glioblastoma